作者：
Michael S,Gordon [1]
;
Geoffrey I,Shapiro [2]
;
John,Sarantopoulos [3]
;
Dejan,Juric [4]
;
Brian,Lu [5]
;
Angeliki,Zarotiadou [6]
;
Jamie N,Connarn [7]
;
Yvan,Le Bruchec [6]
;
Calin Dan,Dumitru [6]
;
R Donald,Harvey [6]
作者单位：
Departments of Hematology and Medical Oncology, HonorHealth Research Institute, Scottsdale, AZ, United States.
[1]
Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
[2]
Department of Medicine, Division of Medical Oncology & Hematology, Institute for Drug Development, Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, United States.
[3]
Massachusetts General Hospital Cancer Center, Boston, MA, United States.
[4]
Department of Medicine, Harvard Medical School, Boston, MA, United States.
[5]
Bristol Myers Squibb, Princeton, NJ, United States.
[6]
Celgene Research S.L.U., a Bristol-Myers Squibb Company, Boudry, Switzerland.
[7]
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University and Emory University School of Medicine, Atlanta, GA, United States.
[8]
DOI
10.3389/fonc.2021.786120
PMID
35070991
发布时间
2022-04-30
换一批
换一批
